首页> Translational research : the journal of laboratory and clinical medicine> Targeting MAFB potentiates immune checkpoint inhibitor efficacy by reprogramming tumor-associated macrophages to an M1-like phenotype in colorectal cancer.

Targeting MAFB potentiates immune checkpoint inhibitor efficacy by reprogramming tumor-associated macrophages to an M1-like phenotype in colorectal cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sang-Pil,Choi

第一单位： Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.

作者： Sang-Pil,Choi ^[1] ; Jun,Yang ^[1] ; In-Byung,Park ^[1] ; Seok-Jin,Kang ^[1] ; Si-Won,Park ^[1] ; Chang-Hee,Lee ^[1] ; Hyeon Jeong,Lee ^[1] ; Joonbeom,Bae ^[1] ; Chang-Yong,Choi ^[2] ; Jiyoon,Shin ^[1] ; Ji-In,Kim ^[1] ; Hyun Yong,Jin ^[3] ; Young Sik,Lee ^[1] ; Taehoon,Chun ^[4]

作者单位： Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea. ^[1] Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, School of Medicine, Baltimore, MD 21201, USA. ^[2] Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA. ^[3] Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea. Electronic address: tchun@korea.ac.kr. ^[4]

关键词 Colorectal cancer Immune checkpoint inhibitor MAFB Tumor microenvironment Tumor-associated macrophage